Everything below concerns Somatotroph. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake in single-use vials |
| Solubility class | Freely soluble in water | Reconstituted with sterile diluent before injection |
| Typical storage temperature | 2 to 8 degrees Celsius | Before reconstitution; protect from light |
| Typical analytical method | Reversed-phase high-performance liquid chromatography | Purity and related-substance testing |
| Identity confirmation | Mass spectrometry | Observed mass near 5.1 kDa for the intact peptide |
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
After the final primary election, Clinton became the presumptive Democratic nominee. On July 12, Sanders formally endorsed Clinton. He said he would continue to work with the Democratic National Convention organizers to implement progressive positions. Sanders refused to formally concede before the convention. He spoke at the 2016 Democratic National Convention on July 25, during which he gave Clinton his full support. Some of his supporters attempted to protest Clinton's nomination and booed when Sanders called for party unity. He responded, "Our job is to do two things: to defeat Donald Trump and to elect Hillary Clinton ... It is easy to boo, but it is harder to look your kids in the face if we are living under a Trump presidency." On November 8, in the general election, Sanders received almost 6% of the vote in Vermont, even though he was no longer a candidate. This was the highest share of a statewide presidential vote for a write-in draft campaign in American history. He also received more votes in Vermont than Gary Johnson, the Libertarian candidate, and Jill Stein, the Green candidate, combined. It was possible to vote for Sanders as a write-in candidate in 12 states, and exact totals of write-in votes for him were published in three of them: California, New Hampshire, and Vermont. In those three states, he received 111,850 write-in votes, about 15% of the write-in votes nationwide, and less than 1% of total nationwide vote.
== Premise == One decade after most members of the Justice Society of America (JSA) are killed in battle against the Injustice Society of America (ISA), Courtney Whitmore, a high school student who moved to Blue Valley, discovers the Cosmic Staff of Starman and learns that her stepfather Pat Dugan used to be his sidekick. After encountering the remnants of the ISA which now include the mysterious Dragon King and his daughter Cindy Burman, Courtney becomes the inspiration for a whole new generation of superheroes and recruits Yolanda Montez, Rick Tyler, and Beth Chapel. In the second season, Stargirl and the JSA contend with the re-emergence of former ISA member Shade and a mysterious entity known as Eclipso, who works with Cindy to create a new ISA called Injustice Unlimited. When Eclipso breaks free from Cindy's control, the JSA works to stop him and finds new allies in Jennie-Lynn Scott, Jakeem Williams, Thunderbolt, a rescued Charles McNider, a revived Starman, and former ISA members Solomon Grundy, Sportsmaster, and Tigress. In the third and final season, the heroes and villains living in Blue Valley become embroiled in a murder mystery after former ISA member Steven Sharpe is found dead, while someone has been spying on them with cameras placed all over town. It turns out that a reconstituted Icicle was responsible as he is in league with the JSA's old enemy Ultra-Humanite and a surviving Dragon King.
=== Death === Ingestion of high quantities of capsaicin can be deadly, particularly in people with heart problems. Even healthy young people can suffer adverse health effects like myocardial infarction after ingestion of capsaicin capsules.
In April 2023, Monster Beverage Corporation sued independent videogame developer Glowstick Entertainment for their horror party game Dark Deception: Monsters and Mortals. Apparently to Monster Beverage, the use of "Monster" in the title of the game and their green and black logo make it "very confusing" because of the similarities between the two. Glowstick Entertainment's head creator, Vincent Livings, had decided to fight it in court and has since won the case. Additionally later that month, it was discovered that over 100 trademark complaints had been filed in Japan, including complaints against the Pokémon (1996–), Monster Hunter (2004–), and Monster Musume (2012–) franchises, the first of which predates the Monster Energy brand by over half a decade.
== Military detention == Annually, the Israeli military arrests approximately 500 to 700 Palestinian children, all under the age of 18. As reported by Addameer, a Palestinian NGO, about 200 of these children remain incarcerated in Israeli prisons. Following the commencement of Israel's aggressive actions in Gaza on 7 October, there has been a noticeable surge in detentions - with over 450 children being taken into custody at various points, as stated by the Palestinian Commission for Detainees and Ex-Detainees Affairs. Since the year 2000, an estimated 13,000 children have been subject to arbitrary detention, interrogation, trial in military courts, and imprisonment. Many Palestinian children are detained in nighttime operations, with some being placed in administrative detention without a fair trial or formal charges. According to Lawyers for Palestinian Human Rights, there are numerous significant human rights issues associated with these procedures. In May 2024, the Israeli military publicly identified several Palestinian children, alleging that they had been acting as Hamas informants, leading the United Nations Special Rapporteur on the occupied Palestinian territories to state the Israeli army often forces detained Palestinian children to become informants. In April 2025, it was reported that Walid Ahmad was the first Palestinian child to die in Israeli prisons. Ahmad was arrested six months prior to his death and kept at the Megiddo Prison after being accused of throwing stones at soldiers in the occupied West Bank.
Sources: en.wikipedia.org
== Further reading == Touraine, P. (2005). "Breast Inflammatory Gigantomastia in a Context of Immune-Mediated Diseases". Journal of Clinical Endocrinology & Metabolism. 90 (9): 5287–5294. doi:10.1210/jc.2005-0642. PMID 15972574. Oladele, AO; Olabanji, JK; Alabi, GH (2007). "Reduction mammoplasty: The experience in Ile-Ife, Nigeria". Nigerian Journal of Medicine. 16 (3): 261–267. PMID 17937167. Netscher, David T.; Mosharrafa, ALI M.; Laucirica, Rodolfo (1996). "Massive Asymmetric Virginal Breast Hypertrophy". Southern Medical Journal. 89 (4): 434–7. doi:10.1097/00007611-199604000-00019. PMID 8614890. U.S.A. Library of Congress - Healthy Breasts: A Primer John Blair Deaver (1917). The Breast: Its Anomalies, Its Diseases, and Their Treatment. P. Blakiston's Son & Co. p. 102. Joseph, Jacques (1987). Rhinoplasty and facial plastic surgery with a supplement on mammaplasty and other operations in the field of plastic surgery of the body: an atlas and textbook. Phoenix: Columella Press. p. 755. ISBN 0-9605972-1-2. Plummer, Samuel C.; Bump, Warner S. (1927). "Massive Hypertrophy of the Breasts". Annals of Surgery. 85 (1): 61–6. doi:10.1097/00000658-192701000-00008. PMC 1399262. PMID 17865606. Warren, John Collins (1900). The International text-book of surgery. Vol. II. Saunders. p. 234. Erichsen, John Eric (1885). The Science and art of surgery. Vol. II. H. C. Lea's Son & Company. pp. 693–694. Ochsner, Albert John (1921). Surgical Diagnosis and Treatment: By American Authors. Lea & Febiger. p. 147.
=== Psychotherapy === Long-term, consistent psychotherapy is the preferred method for treating BPD, and engagement in any therapeutic approach tends to surpass the absence of treatment, particularly in diminishing self-harm impulses. Among the effective psychotherapeutic approaches, dialectical behavior therapy (DBT), schema therapy, and psychodynamic therapies have shown efficacy, although improvements may require extensive time, often years of dedicated effort. Available treatments for BPD include dynamic deconstructive psychotherapy (DDP), mentalization-based treatment (MBT), schema therapy, transference-focused psychotherapy, dialectical behavior therapy (DBT), and general psychiatric management. The effectiveness of these therapies does not significantly vary between more intensive and less intensive approaches. Transference-focused psychotherapy is designed to mitigate absolutist thinking by encouraging individuals to express their interpretations of social interactions and their emotions, thereby encouraging more precise and flexible categorizations. Dialectical behavior therapy (DBT), on the other hand, focuses on developing skills in four main areas: interpersonal communication, distress tolerance, emotional regulation, and mindfulness, aiming to equip individuals with BPD with tools to manage intense emotions and improve interpersonal relationships.
== Discovery == In a screen for genes involved in apoptosis, Yasumasa Ishida, Tasuku Honjo and colleagues at Kyoto University in 1992 discovered and named PD-1. In 1999, the same group demonstrated that mice where PD-1 was knocked down were prone to autoimmune disease and hence concluded that PD-1 was a negative regulator of immune responses. In 2025, Yasumasa Ishida was part of a group that found that PD-1, together with its extracellular ligand "PD-L1" (the name given to the single gene precursor of both PD-L1 and PD-L2 genes in tetrapod species) and cytoplasmic tail binding phosphatases SHP-1 and SHP-2, and their interaction motifs, are well-conserved in evolution throughout jawed vertebrates (from the level of sharks) (Figure 2). This corroborated partial findings by others.
=== Flexible rechargeable battery electrode === Graphene oxide has been demonstrated as a flexible free-standing battery anode material for room temperature lithium-ion and sodium-ion batteries. It is also being studied as a high surface area conducting agent in lithium-sulfur battery cathodes. The functional groups on graphene oxide can serve as sites for chemical modification and immobilization of active species. This approach allows for the creation of hybrid architectures for electrode materials. Recent examples of this have been implemented in lithium-ion batteries, which are known for being rechargeable at the cost of low capacity limits. Graphene oxide-based composites functionalized with metal oxides and sulfides have been shown in recent research to induce enhanced battery performance. This has similarly been adapted into applications in supercapacitors, since the electronic properties of graphene oxide allow it to bypass some of the more prevalent restrictions of typical transition metal oxide electrodes. Research in this field is developing, with additional exploration into methods involving nitrogen doping and pH adjustment to improve capacitance. Additionally, research into reduced graphene oxide sheets, which display superior electronic properties akin to pure graphene, is currently being explored. Reduced graphene oxide greatly increases the conductivity and efficiency, while sacrificing some flexibility and structural integrity.
26 June – 2024 United Kingdom general election betting scandal Alex Cole-Hamilton, leader of the Scottish Liberal Democrats, admits to placing bets on Scottish Liberal Democrat election candidates, but says he did not place bets on the date of the election itself. The Sun reports that Sir Philip Davies, the Conservative candidate for Shipley, allegedly placed an £8,000 bet on whether he would lose his seat at the election, which has a majority of 6,242. Police arrest a woman in her 20s in connection with the Westminster "honeytrap" scandal in which a number of MPs were sent unsolicited text messages, some of them explicit. Mishal Husain moderates The Prime Ministerial Debate, the BBC's head-to-head debate between Rishi Sunak and Keir Starmer. Welsh Labour suspends Rhianon Passmore, the Senedd member for Islwyn, pending investigation following an allegation she was seen driving a car with two different number plates. The Social Democratic and Labour Party (SDLP) launches its election manifesto, which includes a "Marshall Plan" to address the backlog in Northern Ireland's health service, reforms to Stormont, and a repeal of the Troubles Legacy Act. 27 June – The Metropolitan Police says that at least seven police officers are now being investigated for placing bets on the date of the general election. Reform UK condemns campaigners in Clacton who were filmed by an undercover reporter for Channel 4 News making racist, homophobic and Islamophobic comments, including one who used a racial slur to describe Prime Minister Rishi Sunak.
Sources: en.wikipedia.org
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.
The primary measure is usually a cross-sectional abdominal scan that separates internal fat from fat just under the skin. Waist circumference and body weight are recorded as secondary measures because they are easy to obtain but do not distinguish the two fat compartments. Hormone and metabolic blood tests are collected alongside the imaging.
Available follow-up data indicate that visceral fat drifts back toward pretreatment levels once injections stop. The change is therefore best described as treatment-dependent rather than permanent. Investigators continue to debate whether intermittent or repeated courses would preserve any benefit.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.